Depletion of estrogen receptor in human breast tumor cells by a novel substituted indole that does not bind to the hormone binding domain

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 1, 1996, Pages 21-30

  Bitonti, Alan J ^a   Dumont, Jennifer A ^a   Salituro, Francesco G ^a,b   McDonald, Ian A ^a,c   Jarvi, Esa T ^a   Frey, Lisa M ^a   Wright, Paul S ^a   Baumann, Russell J ^a  

^a Merrell Dow Research Institute   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c SIBIA Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; INDOLE DERIVATIVE; MDL 101906; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST TUMOR; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; TUMOR CELL;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0030130526     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00006-4     Document Type: Article

References (42)

1. 1. Henderson I. C., Harris J. R., Kinne D. W. and Hellman S.: Cancer of the Breast. In: Cancer: Principles and Practice of Oncology 3rd Edition, (Edited by V. T. DeVita, Jr., S. Hellman and S. A. Rosenberg). J. B. Lippincott Co., Philadelphia, PA (1989) pp. 1197-1268.
2. 2. Arafah B. M. and Pearson O. H.: Endocrine Treatment of Advanced Breast Cancer. In: Estrogen/Antiestrogen Action and Breast Cancer Therapy (Edited by V. C. Jordan) University of Wisconsin Press, Madison, WI (1986) pp. 417-430.
3. 3. Jordan V. C. and Murphy C. S.: Endocrine Pharmacology of Antiestrogens as Antitumor Agents. Endocrine Rev. 11 (1990) 578-610.
4. 4. Katzenellenbogen B. S.: Antiestrogen Resistance: Mechanisms by Which Breast Cancer Cells Undermine the Effectiveness of Endocrine Therapy. J. Natl. Cancer Inst. 83 (1991) 1434-1435.
5. 5. Graham M. L., Krett N. L., Miller L. A., Leslie K. K., Gordon D. F., Wood W. M., Wei L. L. and Horwitz K. B.: T47DCO Cells, Genetically Unstable and Containing Estrogen Receptor Mutations, Are a Model for the Progression of Breast Cancers to Hormone Resistance. Cancer Res. 50 (1990) 6208-6217.
6. 6. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W. and McGuire W. L.: Variant Human Breast Tumor Estrogen Receptor with Constitutive Transcriptional Activity. Cancer Res. 51 (1991) 105-109.
7. 7. Castles C. G., Fuqua S. A. W., Klotz D. M. and Hill S. M.: Expression of a Constitutively Active Estrogen Receptor Variant in the Estrogen Receptor-negative BT20 Human Breast Cancer Cell Line. Cancer Res. 53 (1993) 5934-5939.
8. 8. Osborne C. K., Coronado E., Allred D. C., Wiebe V. and DeGregorio M.: Acquired Tamoxifen Resistance: Correlation with Reduced Breast Tumor Levels of Tamoxifen and Isomerization of trans-4-Hydroxytamoxifen. J. Natl. Cancer Inst. 83 (1991) 1477-1482.
9. 9. Osborne C. K., Wiebe V. J., McGuire W. L., Ciocca D. R. and DeGregorio M. W.: Tamoxifen and the Isomers of 4-Hydroxytamoxifen in Tamoxifen-Resistant Tumors from Breast Cancer Patients. J. Clin. Oncol. 10 (1992) 304-310.
10. 10. Johnston S. R. D., Haynes B. P., Smith I. E., Jarman M., Sacks N. P. M., Ebbs S. R. and Dowsett M.: Acquired Tamoxifen Resistance in Human Breast Cancer and Reduced Intra-tumoral Drug Concentration. The Lancet 342 (1993) 1521-1522.
11. 11. King R. J. B., Wang D. Y., Daly R. J. and Darbre P. D.: Approaches to Studying the Role of Growth Factors in the Progression of Breast Tumours from the Steroid Sensitive to Insensitive State. J. Steroid Biochem. 34 (1989) 133-138.
12. 12. Kern F. G., Cheville A. L. and Liu Y.: Growth Factor Receptors and the Progression of Breast Cancer. Sem. Cancer Biol. 1 (1990) 317-328.
13. 13. King R. J. B.: Receptors, Growth Factors, and Steroid Insensitivity of Tumours. J. Endocrinol. 124 (1990) 179-181.
14. 14. Pavlik E. J., Nelson K., Srinivasan S., Powell D. E., Kenady D. E., DePriest P. D., Gallion H. H. and van Nagell J. R. Jr.: Resistance to Tamoxifen with Persisting Sensitivity to Estrogen: Possible Mediation by Excessive Antiestrogen Binding Site Activity. Cancer Res. 52 (1992) 4106-4112.
15. 15. Leeuwen F. E., Benraadt J., Coebergh J. W. W., Kiemeney L. A. L. M., Gimbrere C. H. F., Otter R., Schouten L. J., Damhuis R. A. M., Bontenbal M., Diepenhorst F. W., vanden Belt-Dusebout A. W. and van Tinteren H.: Risk of Endometrial Cancer after Tamoxifen Treatment of Breast Cancer. The Lancet 343 (1994) 448-452.
16. 16. Hard G. C., Iatropoulos M. J., Jordan K., Radi L., Kaltenberg O. P., Imondi A. R. and Williams G. M.: Major Difference in the Hepatocarcinogenicity and DNA Adduct Forming Ability between Toremifene and Tamoxifen in Female Cr1: CD(BR) Rats. Cancer Res. 53 (1993) 4534-4541.
17. 17. Thompson E. W., Katz D., Shima T. B., Wakeling A. E., Lippman M. E. and Dickson R. B.: ICI 164,384, a Pure Antagonist of Estrogen-stimulated MCF-7 Cell Proliferation and Invasiveness. Cancer Res. 49 (1989) 6929-6934.
18. 18. Wakeling A. E., Dukes M. and Bowler J.: A Potent Specific Pure Antiestrogen with Clinical Potential. Cancer Res. 51 (1991) 3867-3873.
19. 19. Gibson M. K., Nemmers L. A., Beckman W. C. Jr., Davis V. L., Curtis S. W. and Korach K. S.: The Mechanism of ICI 164,384 Antiestrogenicity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue. Endocrinol. 129 (1991) 2000-2010.
20. 20. Dauvois S., Danielian P. S., White R. and Parker M. G.: Antiestrogen ICI 164,384 Reduces Cellular Estrogen Receptor Content by Increasing Its Turnover. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4037-4041.
21. 21. Reese J. C. and Katzenellenbogen B. S.: Examination of the DNA-Binding Ability of Estrogen Receptor in Whole Cells: Implications for Hormone-Independent Transactivation and the Actions of Antiestrogens. Mol. Cell. Biol. 12 (1992) 4531-4538.
22. 22. Fawell S. E., White R., Hoare S., Sydenham M., Page M. and Parker M. G.: Inhibition of Estrogen Receptor-DNA Binding by the 'Pure' Antiestrogen ICI 164,384 Appears to be Mediated by Impaired Receptor Dimerization. Proc. Natl. Acad Sci. U.S.A. 87 (1990) 6883-6887.
23. 23. Kumar V. and Chambon P.: The Estrogen Receptor Binds Tightly to Its Responsive Element as a Ligand-Induced Homodimer. Cell 55 (1988) 145-156.
24. 24. Bowler J., Lilley T. J., Pittam J. D. and Wakeling A. E.: Novel Steroidal Pure Antiestrogens. Steroids 54 (1989) 71-99.
25. 25. Brunner N., Frandsen T. L., Holst-Hansen C., Bei M., Thompson E. W., Wakeling A. E., Lippman M. E. and Clarke R.: MCF7/LCC2: A 4-Hydroxytamoxifen Resistant Human Breast Cancer Variant That Retains Sensitivity to the Steroidal Antiestrogen ICI 182,780. Cancer Res. 53 (1993) 3229-3232.
26. 26. von Angerer E., Biberger C., Holler E., Koop R. and Leichtl S.: 1-Carbamoylalkyl-2-phenylindoles: Relationship Between Side Chain Structure and Estrogen Antagonism. J. Steroid Biochem. Molec. Biol. 49 (1994) 51-62.
27. 27. Anderson F. M. et al.: Current Protocols in Molecular Biology, Vol. 2, John Wiley and Sons, New York (1989) 12.2.
28. 28. Lee W., Mitchell P. and Tjian R.: Purified Transcription Factor AP-1 Interacts with TPA-Inducible Enhancer Elements. Cell 49 (1987) 741-752.
29. 29. Evans R. M.: The Steroid and Thyroid Hormone Receptor Superfamily. Science 240 (1988) 889-895.
30. 30. Chodosh L. A., Baldwin A. S., Carthew R. W. and Sharp P. A.: Human CCAAT-Binding Proteins Have heterologous Subunits. Cell 53 (1988) 11-24.
31. 31. Sutherland R. L. and Baulieu E. E.: Quantitative estimates of cytoplasmic and nuclear oestrogen receptors in chick oviduct. Effect of oestrogen on receptor concentration and subcellular distribution. Eur. J. Biochem. 70 (1976) 531-541.
32. 32. Wakeling A. E.: Anti-hormones and other steroid analogues. In: Steroid Hormones: A Practical Approach (Edited by B. Green and R. E. Leake) IRL Press, Oxford (1987) pp. 219-236.
33. 33. Katzenellenbogen J. A., Johnson H. J. Jr and Myers H. N.: Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 12 (1973) 4085-4092.
34. 34. Murphy L. C. and Sutherland R. L.: Antitumor activity of clomiphene analogs in vitro; relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site. J. Clin. Endocrinol. and Metab. 57 (1983) 373-379.
35. 35. McKnight S. L. and Kingsbury R.: Transcriptional control Signals of a Eukaryotic Protein-Coding. Gene Science 217 (1982) 316-324.
36. 36. Jiang S.-Y. and Jordan V. C.: Growth Regulation of Estrogen Receptor-Negative Breast Cancer Cells Transfected with Complementary DNAs for Estrogen Receptor. J. Natl. Cancer Inst. 84 (1992) 580-591.
37. 37. Tora L., Mullick A., Metzger D., Ponglikitmongkol M., Park I. and Chambon P.: The Cloned Human Oestrogen Receptor Contains a Mutation Which Alters Its Hormone Binding Properties. EMBO J. 8 (1989) 1981-1986.
38. 38. Berry M., Metzger D. and Chambon P.: Role of the Two Activating Domains of the Oestrogen Receptor in the Cell-Type and Promoter-Context Dependent Agonistic Activity of the Anti-oestrogen 4-Hydroxytamoxifen. EMBO J. 9 (1990) 2811-2818.
39. 39. Kiang D. T., Kollander R. E., Thomas T. and Kennedy B. J.: Up-Regulation of Estrogen Receptors by Nonsteroidal Antiestrogens in Human Breast Cancer. Cancer Res. 49 (1989) 5312-5316.
40. 40. Saceda M., Lippman M. E., Chambon P., Lindsey R. L., Ponglikitmongkol M., Puente M. and Martin M. B.: Regulation of the Estrogen Receptor in MCF-7 Cells by Estradiol. Mol. Endocrinol. 2 (1988) 1157-1162.
41. 41. Saceda M., Knabbe C., Dickson R. B., Lippman M. E., Bronzert D., Lindsey R. K., Gottardis M. M. and Martin M. B.: Post-transcriptional Destabilization of Estrogen Receptor mRNA in MCF-7 Cells by 12-O-Tetradecanoylphorbol-13-acetate. J. Biol. Chem. 266 (1991) 17809-17814.
42. R-1. Cancer Res. 54 (1994) 1587-1595.